Citigroup Downgrades Moderna to Sell, Raises Price Target to $80
Citigroup analyst Geoff Meacham downgrades Moderna (NASDAQ:MRNA) from Neutral to Sell and raises the price target from $60 to $80.
Share
Why It Matters
An expert analyst says Moderna stock looks too expensive right now. Even though they raised their price guess, they think it might fall soon.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.